You are here: Industry Insights > Innovent

News List

Innovent Biologics Announces FDA Acceptance of NDA for Pemigatinib in Patients with Previously Treated, Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusions or Rearrangements En-CPhI.CN
December 03, 2019
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology ...
Innovent Presents Co-developed Cancer-Fighting Tyvyt(R) (Sintilimab Injection) at CIIE 2019 with Eli Lilly En-CPhI.CN
December 03, 2019
Innovent Biologics, a multinational biopharmaceutical company, and Eli Lilly and Company presented their co-developed Tyvyt® ...
Tyvyt (Sintilimab Injection), an Innovative PD-1 Inhibitor Jointly Developed by Innovent and Lilly, is Included in the New Catalogue of National Reimbursement Drug List (NRDL) En-CPhI.CN
December 02, 2019
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology ...
Innovent Biologics Announces Positive Updated Result from the Incyte-sponsored Phase II Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma En-CPhI.CN
October 21, 2019
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune ...
Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors En-CPhI.CN
October 12, 2019
Innovent Biologics, Inc. and Hutchison China MediTech Limited announced the expansion of their global collaboration agreement to evaluate the safety and efficacy of Innovent's Tyvyt® (sintilimab injection) ...
Innovent and Chi-Med expand global collaboration for solid tumor treatment biospectrumasia
October 10, 2019
Preclinical studies have suggested that surufatinib is able to inhibit angiogenesis, block the accumulation of tumor associated macrophages and promote infiltration of effector T cells into tumors, all of which could contribute to improve anti-tumor activ
Innovent Biologics Announces a New Placement Raised HK$2,351.33 Million En-CPhI.CN
October 08, 2019
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology ...
Innovent to develop & commercialize a novel diabetes medicine in China biospectrumasia
August 22, 2019
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops and commercializes high-quality medicines, has announced that it has entered into a licensing agreement with Eli Lilly and Company (Lilly) for the development and potential co
Innovent and Shenogen study Tyvyt-SNG1005 combination for cancer pharmaceutical-technology
August 07, 2019
Innovent Biologics and Shenogen Pharma Group have signed a collaboration agreement to evaluate the combination therapy of Innovent’s Tyvyt with Shenogen’s SNG1005, in patients with advanced cancer.
Innovent and Shenogen Announce Collaboration to Evaluate Tyvyt® (Sintilimab injection) in Combination with SNG1005 for the Treatment of Patients with Advanced Cancer prnasia
August 06, 2019
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced the signing of a collaboration agreement with ...

Previous page 1 2 3 4 5 6 7 8 9 Next page